guardant health inc. - GH
GH
Close Chg Chg %
83.59 2.99 3.58%
Closed Market
86.58
+2.99 (3.58%)
Volume: 2.15M
Last Updated:
Mar 25, 2026, 4:00 PM EDT
Company Overview: guardant health inc. - GH
GH Key Data
| Open $84.97 | Day Range 84.51 - 89.25 |
| 52 Week Range 36.36 - 120.71 | Market Cap $10.96B |
| Shares Outstanding 131.17M | Public Float 126.19M |
| Beta 1.68 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$3.31 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 1.73M |
GH Performance
| 1 Week | 1.64% | ||
| 1 Month | -7.80% | ||
| 3 Months | -15.93% | ||
| 1 Year | 100.70% | ||
| 5 Years | -36.14% |
GH Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
27
Full Ratings ➔
About guardant health inc. - GH
Guardant Health, Inc. is a precision oncology company, which engages in the provision of treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions include treatment selection, recurrence detection, and early detection. The company was founded by Helmy Eltoukhy, AmirAli H. Talasaz, and Michael Joseph Wiley in December 2011 and is headquartered in Palo Alto, CA.
GH At a Glance
Guardant Health, Inc.
3100 Hanover Street
Palo Alto, California 94304
| Phone | 1-855-698-8887 | Revenue | 982.02M | |
| Industry | Medical/Nursing Services | Net Income | -416,277,000.00 | |
| Sector | Health Services | 2025 Sales Growth | 32.882% | |
| Fiscal Year-end | 12 / 2026 | Employees | 2,506 | |
| View SEC Filings |
GH Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 13.04 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -33.574 |
| Enterprise Value to Sales | 13.558 |
| Total Debt to Enterprise Value | 0.128 |
GH Efficiency
| Revenue/Employee | 391,867.917 |
| Income Per Employee | -166,112.131 |
| Receivables Turnover | 7.124 |
| Total Asset Turnover | 0.561 |
GH Liquidity
| Current Ratio | 4.843 |
| Quick Ratio | 4.559 |
| Cash Ratio | 3.969 |
GH Profitability
| Gross Margin | 64.46 |
| Operating Margin | -44.429 |
| Pretax Margin | -42.518 |
| Net Margin | -42.39 |
| Return on Assets | -23.792 |
| Return on Equity | N/A |
| Return on Total Capital | -25.842 |
| Return on Invested Capital | -30.271 |
GH Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 106.165 |
| Total Debt to Total Assets | 84.927 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 104.447 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Guardant Health Inc. - GH
Collapse All in section
| All values USD millions. | 2022 | 2023 | 2024 | 2025 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 449.54M | 563.95M | 739.02M | 982.02M | |
Sales Growth
| +20.31% | +25.45% | +31.04% | +32.88% | |
Cost of Goods Sold (COGS) incl D&A
| 157.87M | 227.05M | 289.80M | 349.01M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 35.96M | 42.88M | 42.39M | 39.74M | |
Depreciation
| 33.48M | 40.18M | 40.19M | 38.04M | |
Amortization of Intangibles
| 2.48M | 2.70M | 2.20M | 1.70M | |
COGS Growth
| +27.05% | +43.82% | +27.64% | +20.43% | |
Gross Income
| 291.67M | 336.90M | 449.22M | 633.01M | |
Gross Income Growth
| +16.95% | +15.51% | +33.34% | +40.91% | |
Gross Profit Margin
| +64.88% | +59.74% | +60.79% | +64.46% |
| 2022 | 2023 | 2024 | 2025 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 825.44M | 814.91M | 892.81M | 1.07B | |
Research & Development
| 368.61M | 365.09M | 347.75M | 364.19M | |
Other SG&A
| 456.83M | 449.82M | 545.06M | 705.12M | |
SGA Growth
| +25.44% | -1.28% | +9.56% | +19.77% | |
Other Operating Expense
| - | - | 1.10M | 84.50M | - |
Unusual Expense
| 122.34M | (48.45M) | 44.40M | 5.85M | |
EBIT after Unusual Expense
| (657.22M) | (514.07M) | (488.00M) | (442.15M) | |
Non Operating Income/Expense
| 6.34M | 37.88M | 55.49M | 28.50M | |
Non-Operating Interest Income
| 6.07M | 35.37M | 53.69M | 34.09M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 2.58M | 2.58M | 2.58M | 3.90M | |
Interest Expense Growth
| - | +0.04% | +0.12% | +50.99% | |
Gross Interest Expense
| 2.58M | 2.58M | 2.58M | 3.90M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (653.45M) | (478.76M) | (435.09M) | (417.54M) | |
Pretax Income Growth
| -69.96% | +26.73% | +9.12% | +4.03% | |
Pretax Margin
| -145.36% | -84.90% | -58.87% | -42.52% | |
Income Tax
| 1.14M | 685.00K | 1.28M | (1.26M) | |
Income Tax - Current - Domestic
| 127.00K | 35.00K | 126.00K | 90.00K | |
Income Tax - Current - Foreign
| 1.25M | 1.19M | 871.00K | 352.00K | |
Income Tax - Deferred - Domestic
| - | - | - | 21.00K | - |
Income Tax - Deferred - Foreign
| (257.00K) | (541.00K) | 287.00K | (1.71M) | |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (654.59M) | (479.45M) | (436.37M) | (416.28M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (654.59M) | (479.45M) | (436.37M) | (416.28M) | |
Net Income Growth
| -61.36% | +26.76% | +8.98% | +4.61% | |
Net Margin Growth
| -145.61% | -85.02% | -59.05% | -42.39% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (654.59M) | (479.45M) | (436.37M) | (416.28M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (654.59M) | (479.45M) | (436.37M) | (416.28M) | |
EPS (Basic)
| -6.4064 | -4.2812 | -3.5551 | -3.3203 | |
EPS (Basic) Growth
| -60.00% | +33.17% | +16.96% | +6.60% | |
Basic Shares Outstanding
| 102.18M | 111.99M | 122.75M | 125.37M | |
EPS (Diluted)
| -6.4064 | -4.2812 | -3.5551 | -3.3203 | |
EPS (Diluted) Growth
| -60.00% | +33.17% | +16.96% | +6.60% | |
Diluted Shares Outstanding
| 102.18M | 111.99M | 122.75M | 125.37M | |
EBITDA
| (498.91M) | (519.63M) | (401.21M) | (396.56M) | |
EBITDA Growth
| -29.13% | -4.15% | +22.79% | +1.16% | |
EBITDA Margin
| -110.98% | -92.14% | -54.29% | -40.38% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 130.636 | |
| Number of Ratings | 27 | Current Quarters Estimate | -0.806 | |
| FY Report Date | 03 / 2026 | Current Year's Estimate | -2.974 | |
| Last Quarter’s Earnings | -1.00 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -3.32 | Next Fiscal Year Estimate | -1.985 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 11 | 11 | 11 | 13 |
| Mean Estimate | -0.81 | -0.76 | -2.97 | -1.99 |
| High Estimates | -0.68 | -0.70 | -2.77 | -1.08 |
| Low Estimate | -0.89 | -0.82 | -3.17 | -2.66 |
| Coefficient of Variance | -8.54 | -3.97 | -4.19 | -25.94 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 19 | 20 | 20 |
| OVERWEIGHT | 4 | 4 | 3 |
| HOLD | 4 | 4 | 2 |
| UNDERWEIGHT | 0 | 0 | 1 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Guardant Health Inc. - GH
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Guardant Health Inc. - GH
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Mar 3, 2026 | Steve E. Krognes Director | 19,053 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 3, 2026 | Steve E. Krognes Director | 618 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jan 12, 2026 | Terilyn Juarez Monroe Chief People Officer | 24,710 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $111.75 per share | 2,761,342.50 |
| Jan 12, 2026 | Terilyn Juarez Monroe Chief People Officer | 21,078 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $112.62 per share | 2,373,804.36 |
| Jan 12, 2026 | Terilyn Juarez Monroe Chief People Officer | 20,990 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $113.44 per share | 2,381,105.60 |
| Jan 7, 2026 | John G. Saia Chief Legal Officer | 62,703 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jan 7, 2026 | Kumud Kalia Chief Information Officer | 37,142 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jan 7, 2026 | Kumud Kalia Chief Information Officer | 24,286 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jan 7, 2026 | John G. Saia Chief Legal Officer | 5,688 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jan 7, 2026 | John G. Saia Chief Legal Officer | 5,002 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jan 7, 2026 | John G. Saia Chief Legal Officer | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jan 7, 2026 | John G. Saia Chief Legal Officer | 2,922 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jan 7, 2026 | John G. Saia Chief Legal Officer | 52,714 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $102.14 per share | 5,384,207.96 |
| Jan 7, 2026 | John G. Saia Chief Legal Officer | 54,090 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jan 7, 2026 | John G. Saia Chief Legal Officer | 52,423 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jan 7, 2026 | Christopher Freeman Chief Commercial Officer | 17,684 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jan 7, 2026 | Helmy Eltoukhy Co-Chief Executive Officer; Director | 95,989 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jan 7, 2026 | Helmy Eltoukhy Co-Chief Executive Officer; Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jan 7, 2026 | Helmy Eltoukhy Co-Chief Executive Officer; Director | 2,062,726 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $102.14 per share | 210,686,833.64 |
| Jan 7, 2026 | Helmy Eltoukhy Co-Chief Executive Officer; Director | 2,073,514 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |